Tazemetostat Expanded Access Program for Adults With Solid Tumors
Patients with a diagnosis listed under "conditions" below are eligible to be considered for the EAP. These conditions must be serious or life-threatening at the time of enrollment and appropriate, comparable, or satisfactory alternative treatments must have been tried without clinical success. Patients with conditions not listed under "conditions" below are not eligible for the tazemetostat EAP.
Epithelioid Sarcoma (Ex-US Only)|Spindle Cell Sarcoma|Sinonasal Carcinoma|Small Cell Carcinoma of the Ovary Hypercalcemic Type|Thoracic Sarcoma|Poorly Differentiated Chordoma|ATRT|Malignant Rhabdoid Tumor of Kidney|Malignant Rhabdoid Tumor of Ovary|Malignant Rhabdoid Tumor|Myxoid Spindle Cell Sarcoma|Epithelioid Malignant Peripheral Nerve Sheath Tumor|Chondrosarcoma|Renal Cell Carcinoma|Myoepithelial Carcinoma|Synovial Sarcoma|Renal Medullary Carcinoma|Malignant Mesothelioma|Desmoplastic Small Round Cell Tumor (DSRCT)|Intramedullary Spinal Cord Schwannomatosis
DRUG: Tazemetostat
Patients with a diagnosis listed under "conditions" below are eligible to be considered for the EAP. These conditions must be serious or life-threatening at the time of enrollment and appropriate, comparable, or satisfactory alternative treatments must have been tried without clinical success. Patients with conditions not listed under "conditions" below are not eligible for the tazemetostat EAP.